A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
← catalyst calendarSponsored by PepGen Inc (industry) · PEPG — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Global PGN-EDO51 development voluntarily discontinued by Sponsor
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-17 | actual | When the study began enrolling |
| Primary completion | 2025-05-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-28 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy (DMD)
Interventions
- Drug: IV infusion
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFAdverse events and serious adverse events (safety and tolerability of PGN-EDO51 during the MAD period)
measured Signing of informed consent to Week 28
Dystrophin levels (MAD period)
measured Baseline to Week 28
Adverse events and serious adverse events (safety and tolerability of PGN-EDO51 during the LTE period)
measured Signing of informed consent to Week 108
Permalink · PEPG's whole pipeline · Catalyst calendar · Every registered study · What changed